| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
iii
|
|
|
|
Introduction
Abstract: Lowering low-density lipoprotein-cholesterol (LDL-C) levels using statins can significantly reduce cardiovascular (CV) risk in patients with dyslipidemia. However, the risk of major vascular...
|
Philip Barter
|
265-266
|
|
|
|
HDL-C: Role as a risk modifier
Abstract: Evidence that low-density lipoprotein-cholesterol (LDL-C) causes cardiovascular disease (CVD) is overwhelming. It has also been proven beyond all doubt that lowering the level of LDL-C using...
|
Philip Barter
|
267-270
|
|
|
|
Pitavastatin: An overview
Abstract: Compared to other statins, pitavastatin is a highly potent 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor and an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-...
|
Yasushi Saito
|
271-276
|
|
|
|
Pitavastatin: Novel effects on lipid parameters
Abstract: Atherogenic dyslipidemia is characterised by high levels of triglycerides, low levels of high-density lipoprotein-cholesterol (HDL-C), and moderate to marked elevations in low-density lipopr...
|
M. John Chapman
|
277-284
|
|
|
|
Pitavastatin: Clinical effects from the LIVES Study
Abstract: Although clinical trials provide useful information on drug safety and efficacy, results do not always reflect those observed in the real world. The Japanese long-term prospective post-marke...
|
Tamio Teramoto
|
285-288
|
|
